No headlines found.
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
Globe Newswire (Thu, 6-Nov 4:03 PM ET)
OnKure Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 4-Nov 4:05 PM ET)
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.
As of February 3, 2026, OKUR stock price declined to $2.40 with 208,764 million shares trading.
OKUR has a beta of 1.70, meaning it tends to be more sensitive to market movements. OKUR has a correlation of 0.14 to the broad based SPY ETF.
OKUR has a market cap of $32.52 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, VXF, IWC.
OKUR has underperformed the market in the last year with a price return of -61.0% while the SPY ETF gained +15.8%. OKUR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.2% and -20.0%, respectively, while the SPY returned +1.4% and -0.3%, respectively.
OKUR support price is $2.50 and resistance is $2.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.
